Use of PRP in Endometrial Reconstruction
Endometrial Reconstruction by Human Regenerative Factors Derived From Platelet-Rich Plasma in Mice Models
1 other identifier
observational
10
1 country
1
Brief Summary
Infertility, which affected 48.5 million couples worldwide in 2010 alone, has many causes; some causes result from issues related to the endometrium. Unfortunately, no cure exists for medical conditions resulting in the destruction of the endometrium, or for non-functional uterus. Thus, safe and effective therapies are needed to treat these diseases and to establish fertility in affected women. These novel techniques refer to the use and application of regenerative/paracrine factors to regenerate the endometrium in patients with Asherman's Syndrome (AS) and Endometrial Atrophy (EA).These new therapies based on the injection of the identified regenerative/paracrine factors and the platelet-rich plasma (PRP) from whole blood in an immunodeficient mouse model with AS/EA, evaluating their contribution and/or effect in the endometrial repair by functional proofs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 8, 2017
CompletedStudy Start
First participant enrolled
July 18, 2017
CompletedFirst Posted
Study publicly available on registry
August 15, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedMarch 13, 2025
March 1, 2025
6.5 years
June 8, 2017
March 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Endometrial thickness after reconstruction in murine model
Using histological and functional technologies demonstration of regeneration ability of PRP
through study completion, an average of 1 year
Eligibility Criteria
Participants diagnosed with Asherman Syndrome and Endometrial Atrophy by Hysteroscopy.
You may qualify if:
- Participants diagnosed with Asherman Syndrome and Endometrial Atrophy by Hysteroscopy.
- No pregnancy after hormonal treatment.
You may not qualify if:
- Psychiatric diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fundación IVIlead
Study Sites (1)
IVI Barcelona
Barcelona, Spain
Related Publications (1)
Cervello I, Gil-Sanchis C, Santamaria X, Cabanillas S, Diaz A, Faus A, Pellicer A, Simon C. Human CD133(+) bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome. Fertil Steril. 2015 Dec;104(6):1552-60.e1-3. doi: 10.1016/j.fertnstert.2015.08.032. Epub 2015 Sep 15.
PMID: 26384164RESULT
Biospecimen
Platelet-Rich Plasma from Whole Blood.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Irene Cervello, PhD
Fundación IVI
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2017
First Posted
August 15, 2017
Study Start
July 18, 2017
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
March 13, 2025
Record last verified: 2025-03